Tiverton Asset Management’s Theravance Biopharma TBPH Stock Holding History

Tiverton Asset Management’s Portfolio TBPH Stock Details TBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$97K	Buy	4,962 +3,420	+222%	+$69.1K	﹤0.01%	646
2019 Q2	$25K	Hold	1,542	–	–	﹤0.01%	676
2019 Q1	$35K	Hold	1,542	–	–	﹤0.01%	637
2018 Q4	$40K	Buy	+1,542	New	+$41.6K	﹤0.01%	468

Other funds holding TBPH

WIM

Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Chescapmanager Baltimore, Maryland $1.17B AUM 42.44% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Tiverton Asset Management's TBPH Position: Q3 2019 in Review

Tiverton Asset Management increased its Theravance Biopharma (TBPH) stake by 222% in Q3 2019, buying an estimated $69.1K and bringing the position to 4,962 shares worth $97K. The position accounts for ﹤0.01% of the portfolio, ranked #646.

Tiverton Asset Management first reported a position in TBPH in Q4 2018 and has held it in 4 quarters since. 92 funds tracked by Wall St. Rank hold TBPH as of Q3 2019.

Tiverton Asset Management held 4,962 shares of Theravance Biopharma worth $97K as of Q3 2019.
Tiverton Asset Management bought 3,420 Theravance Biopharma shares in Q3 2019, an estimated $69.1K.
Theravance Biopharma made up ﹤0.01% of Tiverton Asset Management's portfolio in Q3 2019, its #646 holding.
Tiverton Asset Management first reported a position in Theravance Biopharma in Q4 2018 and has held it in 4 quarters since.
92 funds tracked by Wall St. Rank held Theravance Biopharma as of Q3 2019.

Based on Tiverton Asset Management's 13F filing for Q3 2019, filed 13 Nov 2019.